ClinicalTrials.gg
CompletedNCT03425617Updated Feb 5, 2019

Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD

A Phase 4 interventional study of Tiotropium + Olodaterol and PLACEBO in Chronic Obstructive Pulmonary Disease, sponsored by Queen's University. Completed at 1 site in Canada. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-02-05.

Sponsored by Queen's University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tiotropium · Pulmonary Disease, Chronic Obstructive.

Enrollment
95th of 105
25 · median 131
Started
2017
with 8 others
Phase 4
52 of 105
none open now
Registered
95th of 105
by date

Among the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive, this one is the 95th largest by enrollment, is one of 9 that started in 2017, is one of 52 in phase 4, and was the 95th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tiotropium

tiotropium: first FDA approval 2004 (SPIRIVA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The deleterious consequences of lung hyperinflation seem not to be restricted to the respiratory system in patients with chronic obstructive pulmonary disease (COPD). Cardiac function, in particular, is strongly influenced by changes in lung volumes and intra-thoracic pressures. In this context, strategies to reduce lung hyperinflation and the work of breathing can positively impact upon cardiac output and blood flow redistribution to peripheral muscles in these patients. There is growing evidence that combination of bronchodilators of different classes is an efficacious and safe strategy for further improving airflow obstruction and hyperinflation in patients with more advanced COPD. Therefore, we aim to investigate that, compared with placebo, a novel LABA/LAMA fixed combination (tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® (Inspiolto®) (TIO/OLO) would decrease lung volumes at rest and during exercise, thereby improving: 1) central and peripheral hemodynamics and 2) arterial oxygenation, with positive consequences on skeletal muscle oxygenation and exercise tolerance in hyperinflated patients with moderate to very severe COPD.

Read the detailed description

Prospective, proof-of-concept, single-dose study will be conducted using a randomized, double-blind, placebo-controlled, crossover design. Treatment will consist of a single dose of tiotropium 5mcg and olodaterol 5mcg via Respimat (Inspiolto)(TIO/OLO) or placebo; the order of treatment will be randomized. Submaximal cardiopulmonary exercise tests will be performed 1 hour after inhalation of TIO/OLO or placebo. Changes in blood flow index (BFI) measured by near-infrared spectroscopy (NIRS) during exercise will be the primary study endpoint.

Written informed consent will be obtained from all participants prior to performing any study related procedures. Participants will complete: 1) an initial visit to determine eligibility for the study; 2) a run-in visit conducted after 2 weeks of stabilization on short-acting bronchodilator therapy to familiarize subjects with the standardized exercise test (submaximal cardiopulmonary exercise tests) to be used in the subsequent treatment visits; and 3) two treatment visits, randomized to order, conducted 3-7 days apart.

Visit 1 will include:

  1. A thorough medical history;
  2. Clinical assessment;
  3. Chronic activity-related dyspnea evaluation;
  4. Complete pulmonary function testing;
  5. A symptom-limited incremental exercise test on a cycle ergometer to determine maximal exercise capacity (Wmax); and
  6. Post-salbutamol pulmonary function testing for assessment of bronchodilator responsiveness.

Visit 2 will consist of discontinuous submaximal cardiopulmonary exercise testing for familiarization.

Visits 3 and 4 will consist of pulmonary function tests (spirometry, plethysmography), followed by administration of TIO/OLO or placebo. One hour after inhalation, subjects will perform pulmonary function tests (spirometry, plethysmography) followed immediately by the submaximal cardiopulmonary exercise tests.

Procedures Pulmonary function testing: Routine spirometry, body plethysmography, single-breath diffusing capacity of the lung for carbon monoxide (DLCO), and maximum inspiratory/expiratory mouth pressures will be performed according to recommended techniques using automatic equipment (Vmax 229d with Vs62j body plethysmograph; SensorMedics, Yorba Linda, CA). Measurements will be expressed as % of predicted normal values.

Cardiopulmonary exercise testing: Exercise tests will be conducted on an electronically-braked cycle ergometer using a cardiopulmonary exercise testing system (Vmax229d; SensorMedics) in accordance with clinical exercise testing guidelines. Incremental exercise testing at Visit 1 will consist of a steady-state resting period, followed by followed by 1 minute of loadless pedalling, then 10 watt increases in work-rate every minute to the point of symptom-limitation. Maximal work rate (Wmax) will be defined as the highest work rate that the subject is able to maintain for at least 30 seconds. Constant work rate testing will be conducted at all subsequent visits (see below). Measurements will be collected at rest and during exercise while subjects breathe through a mouthpiece and a low-resistance flow transducer with nasal passages occluded by a noseclip. Measurements will include: standard cardiorespiratory, metabolic and breathing pattern parameters collected on a breath-by-breath basis and compared with predicted normal values based on age and height; heart rate by 12-lead electrocardiogram; blood pressure by auscultation; dynamic operating lung volumes derived from IC maneuvers; oxygen saturation (SpO2) by pulse oximetry; arterialized blood gases from earlobe samples; the intensity of perceived leg discomfort and exertional dyspnea rated by the modified 10-point Borg scale. Breath-by-breath measurements will be averaged every 20-seconds throughout exercise. Three main time points will also be evaluated: rest will be defined as the steady-state period after at least 3 minutes of breathing on the mouthpiece while seated at rest on the cycle ergometer before exercise starts (cardiopulmonary parameters will be averaged over the last 20-sec of this period and resting ICs will be collected while breathing on the same circuit immediately after completion of the quiet breathing period); isotime will be defined as the longest duration achieved during all constant load exercise tests, and; end-exercise will be defined as the last 30-sec of loaded pedaling at the 75%Wmax stage (i.e., Tlim).

Submaximal cardiopulmonary exercise tests: constant work rate testing will consist of a steady-state resting period, followed by two stages at unloaded exercise for 5 min and 75% of Wmax to the limit of tolerance (Tlim. min).

Cardiac output and muscle blood flow and deoxygenation: Cardiac output will be assessed continuously by a calibrated signal-morphology impedance cardiography system (PhysioFlow; Manatec Biomedical, France). Near-infrared spectroscopy (NIRS; OxyMon MK III, Artinis Medical Systems, The Netherlands) will be used to evaluate skeletal muscle blood flow and deoxygenation. The optode will be placed laterally over the mid-third of the right vastus lateralis. Deoxy-hemoglobin (HHb) has been selected as a proxy for muscle fractional O2 extraction and expressed relative to maximum values elicited by cuff-induced ischemia. The NIRS system measures indocyanine green (ICG) concentration following a bolus injection of 5 mg of ICG into a forearm vein. ICG injections will be performed during the fourth minute of each exercise stage (unloaded and 75%of maximal work load).

Symptom evaluation. Dyspnea (respiratory discomfort) will be defined as the "sensation of breathing discomfort" and leg discomfort as "the sensation of leg discomfort experienced during pedalling." These sensations will be rated at rest, every minute during exercise and at end-exercise using the modified 10-point Borg scale. Upon exercise cessation, subjects will be asked to verbalize their main reason for stopping exercise, i.e., breathing discomfort, leg discomfort, combination of breathing and leg discomfort or some other reason to be specified.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥50 years;
  2. Male or female gender;
  3. Long-term history of active smoking;
  4. Signs and symptoms of with adequate treatment according to the GOLD recommendations for at least 3 months (1);
  5. A modified MRC dyspnea score ≥2 or a Baseline Dyspnea Index ≤8;
  6. Resting lung hyperinflation as demonstrated by inspiratory capacity \<80% predicted or functional residual capacity >120% predicted at Visit 1;
  7. Objective evidence of dynamic hyperinflation (a decrease in inspiratory capacity from rest >200 mL)(24,25) and peak exercise dyspnea (breathing discomfort) ≥ leg discomfort scores during the incremental cardiopulmonary exercise test at Visit 1;
  8. A positive "volume" response (≥200 mL increase in inspiratory capacity) to a bronchodilator (400μg salbutamol) at Visit 1
  9. Ability to perform all study procedures and provide/sign .

Exclusion criteria

Exclusion Criteria:

  1. Asthma or other concomitant pulmonary disease;
  2. Use of oral in the preceding month;
  3. Orthopedic/rheumatological limitation precluded cycling;
  4. Type I or non-controlled type II diabetes mellitus or other endocrine diseases;
  5. Unstable angina, life-threatening cardiac arrhythmias, use of an implantable defibrillator;
  6. Myocardial infarction within the previous 6 months;
  7. History of long syndrome (or prolonged corrected QT interval (>450 ms during screening);
  8. abnormality;
  9. History of exercise-induced syncope;
  10. Any for exercise testing;
  11. Inability to understand and cooperate with the procedures.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Tiotropium + Olodaterol first

    tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4

    Drug: Tiotropium + Olodaterol · Other: PLACEBO

  • Experimental
    PLACEBO FIRST

    Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4

    Drug: Tiotropium + Olodaterol · Other: PLACEBO

Interventions

06

What researchers measure

Primary outcomes

  1. Blood Flow Index (BFI)

    Near infrared spectroscopy (NIRS)-derived muscle ICG difference divided by the rise time from 10 to 90% of peak.

    Time frame: 1 day

Secondary outcomes

  1. Cardiac output

    Cardiac output measured by thoracic cardioimpedance

    Time frame: 1 day

  2. Muscle oxygenation

    Deoxy-hemoglobin (HHb) has been selected as a proxy for muscle fractional O2 extraction and expressed relative to maximum values elicited by cuff-induced ischemia.

    Time frame: 1 day

  3. Tlim

    Exercise tolerance during hugh intensity constant load exercise test (75% of peak workload)

    Time frame: 1 day

  4. Exercise dyspnea

    Borg score rated during isotime and peak exercise

    Time frame: 1 day

  5. Inspiratory capacity

    Inspiratory capacity, inspiratory reserve volume measured at rest, isotime and peak exercise

    Time frame: 1 day

  6. Inspiratory reserve volume

    Inspiratory reserve volume measured at rest, isotime and peak exercise

    Time frame: 1 day

07

Study locations

1 site
  • Kingston General Hospital
    Kingston, Ontario k7l2v7, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2018, 17 months.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 17 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 7, 2018
StartActual
Jan 1, 2017
Primary completionActual
Jun 30, 2018
CompletionActual
Jun 30, 2018
Last update
Feb 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03425617
Lead sponsor
Queen's University
Responsible party
Dr. J. Alberto Neder (Clinical professor, Queen's University) — Principal investigator
First posted
Feb 7, 2018
Start date
Jan 1, 2017
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018
Last update
Feb 5, 2019

Study contacts

J Alberto Neder, Prof
principal investigator · Queen'sUniversity/Kingston General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tiotropium · Olodaterol

Start the discussion